---
title: "Economic Study Backs Hexavalent Vaccine Integration for India's National Health Program"
url: https://projectchintan.com/article/india-hexavalent-vaccine-uip-efficiency-study-ssxhw
publisher: Project Chintan
author: Project Chintan Newsroom
section: India
published: 2026-08-04T20:55:09.000Z
modified: 2026-08-05T02:00:49.273Z
language: en-IN
---

# Economic Study Backs Hexavalent Vaccine Integration for India's National Health Program

Integrating a six-in-one vaccine into the Universal Immunisation Programme could streamline delivery for 26 million infants annually while reducing system-wide logistics pressure. Research indicates that lowering procurement costs by half would allow operational savings to exceed the initial acquisi

## Key takeaways

- A six-in-one vaccine could replace current multiple-injection schedules for 26 million infants in India.
- Economic efficiency depends on vaccine price, with a 50% price reduction potentially offsetting all acquisition costs.
- The hexavalent format reduces cold-chain requirements, syringe waste, and time demands on healthcare workers and parents.
- Stakeholder research indicates a strong preference among caregivers for fewer injections during infant immunisation visits.

## Efficiency Gains Through Combination Vaccines

A collaborative study involving the Union Health Ministry and the George Institute for Global Health India suggests that adopting hexavalent vaccines would significantly enhance the efficiency of the Universal Immunisation Programme (UIP). This single injection protects infants against diphtheria, tetanus, pertussis, Hepatitis B, Haemophilus influenzae type b, and polio. Currently, the national schedule requires multiple separate injections, which increases the burden on healthcare providers and the time commitments required from caregivers.

## Why It Matters

India vaccinates approximately 26 million infants every year. Moving to a hexavalent format would minimize the physical burden on children while easing the workload for frontline medical staff. Furthermore, the transition would reduce the demand for cold-chain storage and lower the volume of syringes required. Susmita Chatterjee, Program Head of Health Economics at the George Institute, noted that while procurement costs are higher, the combination format simplifies programs and improves convenience for families.

## Key Facts

- The hexavalent vaccine targets six diseases: diphtheria, tetanus, pertussis, Hepatitis B, Hib, and polio.
- Research was conducted by the Union Health Ministry, the Gates Foundation, Gavi, and John Snow India Private Limited.
- A 50% drop in vaccine pricing would make operational savings greater than the cost of procurement.
- The study analyzed cost factors including healthcare worker time, cold-chain logistics, and household impacts.
- Findings were published in the peer-reviewed journal Human Vaccines & Immunotherapeutics.

## Economic and Operational Outlook

Researchers evaluated two primary scenarios for deployment: substituting the current pentavalent and fractional IPV doses with the six-in-one shot, and replacing both the initial schedule and the DTP booster. The analysis confirms that vaccine price remains the primary driver of total program costs. If acquisition costs are managed, the reduction in injections would alleviate pressure on India's medical infrastructure and meet caregiver preferences for fewer needles per visit.

Source: The Hindu — National

---
Canonical: https://projectchintan.com/article/india-hexavalent-vaccine-uip-efficiency-study-ssxhw
Reported from: The Hindu — National